In-House R&D Deduction for Pharmaceutical Companies Under

Pharmaceutical companies engaged in research and development (R&D) are eligible for significant tax deductions under Section 45(2) of the Direct Tax Code (DTC) 2025. This provision allows deduction for expenditure on scientific research incurred on in-house R&D facilities. This guide analyses the Section 45(2) deduction and its application to pharmaceutical companies.

The R&D Deduction Framework Under Section 45(2)

Section 45(2)(i) — Deduction for In-House R&D

Section 45(2)(i) provides that "A deduction shall be allowed in respect of any expenditure on scientific research incurred (not being expenditure in the nature of cost of any land or building) by a company engaged in the business of:

Bio-technology; or
Manufacture or production of any article or thing, which is not specified in Schedule XIII"

The deduction is allowed on in-house research and development facility as approved by the prescribed authority, subject to the conditions and manner as may be prescribed.

Section 45(2)(ii) — No Deduction for Approved Companies

No deduction shall be allowed under this sub-section to a company approved under sub-section (3)(b)(ii).

Section 45(2)(iii) — No Deduction Under Other Provisions

No deduction shall be allowed in respect of the expenditure mentioned in Section 45(2)(i) under any other provision of the DTC.

Section 45(2)(v) — Scope of Expenditure on Scientific Research

"Expenditure on scientific research" in relation to drugs and pharmaceuticals, shall include expenditure incurred on:

Clinical drug trial
Obtaining approval from any regulatory authority under any Central Act or State Act or Provincial Act
Filing an application for a patent under the Patents Act, 1970

Eligibility Conditions

1. Company Status

The deduction is available only to companies, not to individuals, firms, or other entities. The company must be engaged in:

Bio-technology; or
Manufacture or production of any article or thing not specified in Schedule XIII (which contains items like beer, wine, tobacco, cosmetics, toothpaste, aerated waters, etc.)

2. In-House R&D Facility

The deduction is for expenditure incurred on an in-house research and development facility. The facility must be approved by the prescribed authority.

3. Nature of Expenditure

The expenditure must be on scientific research, not being in the nature of cost of any land or building. The expenditure must be incurred on in-house R&D.

4. Approval by Prescribed Authority

The facility must be approved by the prescribed authority. Under Rule 29(2), the prescribed authority for the purposes of Section 45(2) is the Secretary, Department of Scientific and Industrial Research (DSIR), Government of India.

The Approval Process

Rule 29(2) — Approval by DSIR

Rule 29(2) provides that:

The prescribed authority shall be Secretary, DSIR
No company shall be entitled for deduction under Section 45(2), unless it enters into an agreement with the prescribed authority for co-operation in research and development facility and fulfils such conditions with regard to maintenance of books of account and audit thereof and furnishing of reports
The application for entering into an agreement shall be made by a company in Form No. 11

Rule 29(2)(d) — Order of Approval

The prescribed authority shall:

If satisfied that the conditions mentioned in Section 45(2) are fulfilled, pass an order in writing in Form No. 14, approving the facility within four months from the end of the month in which application is received
Where an application is rejected, a reasonable opportunity of being heard shall be granted to the company
Furnish a copy of such order to the Chief Commissioner of Income-tax having jurisdiction over such company

Rule 29(2)(e) — Conditions for Approval

Approval of expenditure incurred on in-house research and development facility by a company shall be subject to the following conditions:

The facility should not relate purely to market research, sales promotion, quality control, testing, commercial production, style changes, routine data collection or activities of similar nature
The prescribed authority shall furnish electronically its report in Part A of Form No. 12 (approval of facility) and Part B of Form No. 12 (quantifying expenditure)
The report in Form No. 12 shall be furnished electronically to the Chief Commissioner of Income-tax within 120 days of the grant of the approval or of the submission of the audit report

Rule 29(2)(e)(iv) to (viii) — Ongoing Conditions

The company shall maintain separate books of account for each approved facility which shall be audited annually
A report of audit in Form No. 13 shall be furnished electronically to the Secretary, DSIR on or before the due date specified in Section 263(1)(c) for furnishing the return of income, for each succeeding tax year
The company shall attach a copy of such audited annual account with the return of income to be filed under Section 263(1)(a) for each tax year
The company shall ensure that the capital and revenue expenditure on in-house research and development facility is reflected in the schedules or notes to accounts in the audited financial statement
The assets acquired by the approved facility shall be utilised only for the approved purpose and shall not be disposed of without the approval of the Secretary, DSIR

Documents Required

Application Documents

Form No. 11: Application for entering into an agreement for in-house R&D facility
Detailed project report on the R&D facility
Details of the expenditure to be incurred
Expected date of completion of the facility

Post-Approval Documents

Form No. 14: Order of approval from DSIR
Separate books of account for the approved facility
Annual audit report in Form No. 13
Audited annual accounts attached with the return of income
Report in Form No. 12 from DSIR

Practical Compliance for Pharmaceutical Companies

1. Apply Early

Apply for approval well in advance of incurring the R&D expenditure. The DSIR approval process takes time, and the deduction is available only for expenditure incurred on an approved facility.

2. Maintain Separate Books of Account

Maintain separate books of account for the approved facility. This is essential for claiming the deduction and for audit purposes.

3. Get Annual Audit

Get the books of account audited annually by an accountant. The audit report must be furnished in Form No. 13.

4. File Reports Timely

File all reports timely, including:

The audit report in Form No. 13
The audited annual accounts with the return of income
The report in Form No. 12 from DSIR

5. Utilise Assets for Approved Purpose

Ensure that the assets acquired by the approved facility are utilised only for the approved purpose. The assets should not be disposed of without the approval of DSIR.

6. Reflect Expenditure in Financial Statements

Ensure that the capital and revenue expenditure on the in-house R&D facility is reflected in the schedules or notes to accounts in the audited financial statement.

Consequences of Non-Compliance

Disallowance of Deduction

If the conditions are not fulfilled, the deduction may be disallowed. The Assessing Officer may recompute the total income of the assessee for the relevant tax years.

Interest and Penalty

Non-compliance may also result in:

Interest on tax shortfall
Penalty for incorrect claim
Withdrawal of the approval

Expert Legal Guidance

Anuj Desai & Associates provides comprehensive legal advisory services on in-house R&D deduction under Section 45(2) for pharmaceutical companies. Our direct tax experts help pharma companies understand the deduction conditions, prepare applications, and navigate the DSIR approval process. We assist in application preparation, documentation, and representation before the prescribed authority.

Disclaimer: This article provides general information and does not constitute legal advice. For specific guidance on R&D deduction or any other direct tax matter, please consult qualified legal professionals.

Need Expert Legal Guidance?

Navigating the complex in-house R&D deduction framework under Section 45(2) requires experienced legal counsel. At Anuj Desai & Associates, we provide comprehensive direct tax advisory services, including:

Application Preparation: Assistance with Form No. 11 filing
Approval Process: Guidance on the DSIR approval process
Documentation: Assistance with documentation and audit reports
Representation: Representation before DSIR and income-tax authorities

Compliance Guidein-house R&D deduction pharmaceutical companiesSection 45(2) pharma R&Dpharmaceutical R&D deductionin-house R&D facility pharmaSection 45(2) pharma companiesR&D deduction pharmaceuticalDSIR approval pharma R&DForm 11 in-house R&Dpharmaceutical R&D tax benefitSection 45(2) conditions pharmain-house R&D deduction pharmapharmaceutical R&D approvalDSIR in-house R&D pharmaForm 14 R&D approvalpharmaceutical R&D audit Form 13in-house R&D facility approval pharmaSection 45(2) pharma guidepharmaceutical R&D deduction conditionsDSIR pharma R&D approvalin-house R&D pharma complianceSection 45(2) pharma advisorypharmaceutical R&D tax planningDSIR Form 11 pharmain-house R&D pharma expertSection 45(2) pharma documentationpharmaceutical R&D deduction expertDSIR in-house R&D approval processForm 12 pharma R&Dpharmaceutical R&D complianceSection 45(2) pharma best practices

In-House R&D Deduction for Pharmaceutical Companies Under Section 45(2)